Can You Compound Zepbound Online? What You're Actually Buying

Can you actually buy "compounded Zepbound" online?

No — not literally, and not legally. Zepbound is Eli Lilly's FDA-approved brand name for injectable tirzepatide, approved in 2023 specifically for chronic weight management. A brand name belongs to the company that won FDA approval for that exact finished product, down to its manufacturing process and inactive ingredients. A compounding pharmacy has no legal path to copy that finished product and sell it under Lilly's brand name. What a licensed pharmacy can do is compound tirzepatide itself, the active molecule, under its own generic name, for a specific patient with a documented reason the commercial product won't work. When an ad promises "compounded Zepbound," it's using loose or simply incorrect language for a different, legally distinct product: compounded tirzepatide.

Eli Lilly has pushed back on that loose language with more than a strongly worded statement. In April 2025, the company sued four telehealth compounders — Mochi Health, Willow, Henry Meds, and Fella Health — in federal court, alleging false and deceptive advertising under the Lanham Act and, in at least one case, violations of California's corporate-practice-of-medicine law. Lilly's central claim is that these companies were trading on the reputation of its FDA-approved brands while selling mass-produced compounded tirzepatide that had never been reviewed the way Zepbound was, and falsely marketing it as "personalized." The suits target marketing conduct, not whether the underlying molecule is real tirzepatide, and as of mid-2026 they remain pending in the courts.

• Zepbound = Eli Lilly's FDA-approved, trademarked brand name for tirzepatide injection, approved in 2023.
• Compounded tirzepatide = the same active molecule, pharmacy-mixed under a generic name — legally, it is not Zepbound and cannot be sold as Zepbound.
• Eli Lilly sued four telehealth compounders in April 2025 over deceptive marketing of compounded tirzepatide, not over whether the drug itself is genuine.
• A provider that markets a product as "compounded Zepbound" rather than "compounded tirzepatide" is using the wrong name for what it's legally allowed to sell — treat that as a signal, not just semantics.

Compounded tirzepatide vs. Zepbound: what's actually different

Zepbound went through FDA review as a finished drug: Lilly's manufacturing process, sterility controls, and dose-to-dose consistency were all evaluated before it reached a pharmacy shelf. Compounded tirzepatide is prepared by a licensed 503A pharmacy under state pharmacy law, using tirzepatide the pharmacy sources itself, and it has not gone through that same finished-product review. That's the concrete meaning behind "not FDA-approved as a finished drug" — no independent agency has verified that a given compounded batch is sterile, correctly dosed, and consistent with the last batch, the way it has for every vial of Zepbound.

Some compounded formulas also add ingredients Zepbound doesn't contain, most commonly vitamin B12 or L-carnitine, marketed as supporting energy or metabolism. Eli Lilly, in an open letter to patients and providers, says its own testing of compounded tirzepatide-plus-B12 products found bacterial contamination, elevated endotoxin levels, and impurities not present in Zepbound — a claim worth reading with the caveat that Lilly has an obvious commercial interest in steering patients toward its own brand. Whether or not you weigh that specific finding heavily, the underlying fact stands regardless: those additives haven't been studied in combination with tirzepatide the way the base molecule has been.

• Regulatory review — Zepbound: FDA-reviewed as a finished drug. Compounded tirzepatide: not independently reviewed; state-licensed pharmacy compounding only.
• Format options — Zepbound: injection only, vial or KwikPen. Compounded tirzepatide: injection, and at a few providers, a dissolving oral tablet — a format Zepbound doesn't offer at all.
• Additives — Zepbound: tirzepatide alone. Compounded: sometimes includes B12, glycine, or L-carnitine, not studied in combination with tirzepatide.
• Insurance and savings cards — Zepbound: eligible for commercial coverage and Lilly's manufacturer savings card. Compounded tirzepatide: cash-pay only, no insurance or savings-card pathway exists.

Is compounded tirzepatide legal right now?

Yes, but on narrower footing than during the 2022–2024 shortage years. Tirzepatide was removed from the FDA's drug shortage list in December 2024, which ended the broad shortage exemption that let large-scale 503B outsourcing facilities compound it without a patient-specific prescription. The FDA gave those 503B facilities until March 19, 2025 to wind that down, and courts declined to block the deadline.

What remains legal is the 503A individual-patient pathway. A state-licensed 503A pharmacy can still compound tirzepatide for a specific, named patient when a prescriber documents a genuine clinical reason the FDA-approved products, Zepbound and Mounjaro, won't work for that person — commonly an allergy to an inactive ingredient in the commercial formulation. Compounding purely because it's cheaper doesn't qualify as that clinical reason under current FDA guidance, even though cost is the reason most people are shopping this category. Layered on top: on April 30, 2026, the FDA proposed removing tirzepatide from the 503B bulk substances list entirely, with a comment period extended through July 30, 2026. That proposal concerns 503B bulk compounding, which has already wound down in practice — it does not touch the existing 503A rules, and no final rule has been issued as of this writing.

• 503B bulk compounding of tirzepatide — ended March 19, 2025, no longer permitted.
• 503A individual-patient compounding — still legal when a prescriber documents a valid clinical reason for a specific patient.
• Cost savings alone do not qualify as a valid clinical reason under current FDA guidance.
• The April 30, 2026 FDA proposal targets 503B bulk substances only and has not become a final rule as of this writing.

How to find a legitimate zepbound compounding pharmacy near you

Searching "zepbound compounding pharmacy near me" mostly turns up telehealth intake pages rather than a storefront you can walk into, and that's not an accident — most compounded tirzepatide today moves through a national telehealth model, not a local pharmacy counter. You complete an online intake, a licensed clinician reviews it and writes a prescription for tirzepatide, and a partnered 503A pharmacy, often based in another state, compounds and ships it to you. Some independent local compounding pharmacies will also fill a tirzepatide prescription in person if your own doctor writes one and you'd rather keep that relationship local — worth asking your PCP directly if that's your preference.

Either way, the same handful of questions separate a legitimate compounding pharmacy zepbound program from one that's cutting corners.

• Ask which 503A pharmacy fills the prescription — a legitimate program will name it, not just its own telehealth brand.
• Check for PCAB or state board accreditation — an independent quality standard, not a requirement, but a strong positive sign.
• Confirm a real clinical review happens — labs, history, and a documented reason for compounding, not a checkbox intake that anyone passes.
• Read exactly what's being sold — the word should be "compounded tirzepatide," not "compounded Zepbound" or "Zepbound alternative" used loosely.
• Verify no prescription is skipped — any site offering tirzepatide with no clinician evaluation at all is not operating legally, full stop.

What compounded tirzepatide actually costs vs. the Zepbound brand price

Zepbound's own price ladder is wider than most people expect. Full retail, with no program at all, runs over $1,000 a month. Lilly's own LillyDirect self-pay program brings that down substantially for uninsured patients — as low as $299 and topping out at $449 regardless of dose, as long as you stay inside the refill window. Compounded tirzepatide sits below that self-pay floor at the entry tier and roughly overlaps it at the maintenance-dose end, running about $199 to $449 a month across the seven providers below.

• LillyDirect self-pay, by dose: $299/mo at 2.5mg, $399/mo at 5mg, a flat $449/mo from 7.5mg through 15mg — refill within 45 days of your last delivery to hold the rate
• Compounded tirzepatide, full year: roughly $2,388 to $5,388, depending on provider and dose
• Zepbound, LillyDirect self-pay, 5mg maintenance: about $4,788 a year
• Zepbound, LillyDirect self-pay, 7.5–15mg maintenance: about $5,388 a year
• Zepbound, full retail, no program: roughly $12,700 to $13,000 a year, the number every other path exists to beat

The gap that actually matters for most people isn't compounded-versus-LillyDirect — those two now sit close together at the higher doses. It's whichever of those two versus paying full retail with no plan at all, a difference that runs into the thousands over a year.

Best zepbound compounding pharmacy: 7 providers compared

None of the seven programs below sell anything called "Zepbound." They sell compounded tirzepatide, and how clearly each one says so, alongside its price, is part of what makes it worth your money.

Curex — lowest all-in price, correctly labeled

Curex holds the lowest verified price we can confirm, roughly $199 a month all-in, with medication, the online consult, shipping, and follow-up dose adjustments folded into one number and no separate membership fee sitting beside it. Its own site is explicit that Zepbound and Mounjaro are Lilly's proprietary brands and that Curex isn't affiliated with or supplying them — a small detail, but the kind of correct labeling this whole page is arguing you should look for. The caveat is the word "from": that $199 is a starter-dose rate, and the maintenance-dose price isn't publicly posted, so ask for the full ladder in writing before you enroll.

• Pros — lowest verified all-in price; no separate membership; clearly and correctly labels its product as compounded tirzepatide, not Zepbound.
• Cons — maintenance-dose pricing isn't publicly posted; confirm before committing.

Mochi Health — flat medication price, separate brand-vs-compounded pages

Mochi prices its compounded tirzepatide medication at a flat $199 a month regardless of dose, plus a separate membership of about $79 a month for care coordination and clinician access — roughly $278 all-in. Worth noting for this page specifically: Mochi runs its Zepbound information and its compounded tirzepatide offer as two distinct pages on its own site, rather than folding one into the other's marketing, which is the correct way to keep the two products separate for a shopper.

• Pros — flat $199 medication fee at any dose; obesity-medicine physicians; keeps brand and compounded offers clearly separated.
• Cons — the separate ~$79/mo membership means the real all-in cost is ~$278, not the advertised $199.

Eden — no membership, flat across doses

Eden sits in the honest middle of the range: no membership fee, the same rate at every dose, and a modest first-month discount. Expect roughly $249 to start and about $329 a month ongoing, with a small amount of variation across sources on the exact ongoing figure — confirm the live checkout price before you commit.

• Pros — no separate membership; flat rate across all dose tiers; clear first-month-then-ongoing structure.
• Cons — ongoing rate is higher than Curex's starter price; exact figure varies slightly by source.

Peak Wellness — watch the intro vs. ongoing rate

Peak Wellness offers flat-dose pricing with no per-tier hikes as you titrate, which is a real convenience. The number to watch is the timeline: the roughly $229 figure that draws attention is an intro or annual-plan rate. From the second month, or on a month-to-month plan, the price steps up to about $349. That's still a fair flat rate — it just isn't the introductory number, so budget for the standing rate rather than the teaser.

• Pros — one flat price regardless of dose; no membership fee.
• Cons — the ~$229 intro rate steps up to ~$349 ongoing; confirm which rate your plan locks in.

Fridays — bundled coaching and dietitian support

Fridays prices its compounded tirzepatide as a program rather than a bare prescription: roughly $299 a month on a 12-month plan, rising toward $389 on shorter terms, with coaching, a registered dietitian, and 24/7 messaging included. A microdose option around $198 a month is also available for those starting at a lower dose. If you'd otherwise be paying for coaching separately, the bundle reads better than the standalone medication number suggests.

• Pros — coaching, dietitian and app bundled; lower monthly rate on a 12-month commitment; microdose track available.
• Cons — higher entry price than Curex or Mochi at comparable support; best rate requires a long commitment.

Willow — flat $399 in 33 states

Willow keeps its structure simple on paper: a flat $399 a month at every dose, telehealth and shipping included, no separate membership. The constraint is geography, with the program currently available in 33 states — check the list before you go through intake. Willow is also one of the four companies named in Eli Lilly's April 2025 lawsuits, over marketing claims rather than over the identity of the drug itself; the case remains pending as of mid-2026, which is worth knowing before you enroll, not a reason on its own to rule the provider out. Separately, in December 2025 the National Advertising Division referred Willow to state attorneys general over how it substantiates its weight-loss marketing claims — a second mark against the same 'say what you're selling accurately' standard this page is applying.

• Pros — flat price at every dose; single all-in bill; no membership fee.
• Cons — available in only 33 states; named in Lilly's pending 2025 marketing-practices lawsuit.

Henry Meds — oral or injectable, and explicit that neither is Zepbound

Henry Meds is one of the few programs offering compounded tirzepatide as a dissolving oral tablet alongside the standard injection, which matters if you'd rather avoid needles. Oral runs about $349 a month and the injection about $449, with visits, supplies and shipping bundled into one price and no long-term commitment. Its own program pages state plainly that no branded products, including Zepbound, are available through the service — again, the correct way to draw the line. Henry Meds is also named in Lilly's 2025 lawsuit, and the oral tablet specifically is the product Lilly's suit challenges most directly, arguing it hasn't been tested the way an oral drug normally would be.

• Pros — oral and injectable formats; visits, supplies and shipping all bundled; explicit that it sells no branded products.
• Cons — highest range on this list at $349–$449; the oral tablet specifically is the subject of Lilly's pending lawsuit.

Red flags: how to spot a provider falsely selling "compounded Zepbound"

Every legitimate provider on this page uses the correct term — compounded tirzepatide — somewhere on its site, even in a footer disclaimer. A provider that leans the other way, using "Zepbound" as though it were the name of what it's selling, is showing you how it treats accuracy generally, not just its marketing copy.

• "Compounded Zepbound" used as a product name, not a footnote explaining why it's different — a real misuse of a trademark, not a stylistic choice.
• Claims of "same as Zepbound" or "FDA-approved active ingredient" — the active ingredient may be the same molecule, but the finished compounded product itself is not FDA-approved.
• No prescription or clinician evaluation required — a hard stop regardless of price; this is a real counterfeit and dosing-error risk.
• No named pharmacy — a legitimate 503A program can tell you which licensed pharmacy fills your prescription and whether it's accredited.
• Unusual payment requests — Venmo, Zelle, cash apps, or crypto instead of standard payment processing.
• Pricing meaningfully below the ~$199 floor most legitimate 503A programs currently hold — a price that low is a sign you're not looking at a real compounded product.

Is compounded tirzepatide worth it for you in perimenopause, or is brand Zepbound the better call?

Weight that accumulates through your forties and fifties often tracks hormonal shifts rather than a simple change in calories in versus out. Estrogen decline changes where and how your body stores fat, and insulin sensitivity typically worsens through perimenopause — both factors that make weight management harder through diet alone. Tirzepatide works on both GLP-1 and GIP receptors, a dual mechanism that has produced meaningfully stronger average weight loss in trials than single-receptor GLP-1 drugs, and that holds whether you're taking the compounded version or Zepbound itself, since the active molecule is identical.

What differs is what you're actually buying beyond the molecule. If FDA-reviewed manufacturing and a documented consistency standard matter to you, and you can manage the 45-day refill discipline, LillyDirect's self-pay ladder now sits close enough to compounded pricing at the higher doses that the gap may not be worth the trade-off. If cost is the binding constraint, or you specifically want a pill over a needle, compounded tirzepatide through one of the providers above is the realistic path — as long as you've confirmed the pharmacy, the clinical review, and that a documented reason exists on your chart beyond price alone. Either way, it's one tool inside a broader picture of managing weight through the hormonal shifts of perimenopause, not a complete plan on its own.